vs
爱德华生命科学（EW）与Roper Technologies（ROP）财务数据对比。点击上方公司名可切换其他公司
Roper Technologies的季度营收约是爱德华生命科学的1.3倍（$2.1B vs $1.6B），爱德华生命科学净利率更高（23.1% vs 15.8%，领先7.3%），爱德华生命科学同比增速更快（16.7% vs 11.3%），过去两年Roper Technologies的营收复合增速更高（10.5% vs 9.7%）
爱德华生命科学是总部位于美国加利福尼亚州尔湾的医疗科技企业，专注于人工心脏瓣膜及血流动力学监测领域，其研发的Sapien经导管主动脉心脏瓣膜采用牛组织材质，搭配球囊扩张式钴铬合金支架，可通过导管完成植入。
罗珀技术公司是一家专注于科技领域的控股企业，通过持有并运营多家不同细分赛道的科技公司，在科技产业投资与资产管理领域形成了成熟的业务体系，在全球相关市场具备较高的行业影响力。
EW vs ROP — 直观对比
营收规模更大
ROP
是对方的1.3倍
$1.6B
营收增速更快
EW
高出5.4%
11.3%
净利率更高
EW
高出7.3%
15.8%
两年增速更快
ROP
近两年复合增速
9.7%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.6B | $2.1B |
| 净利润 | $380.7M | $331.0M |
| 毛利率 | 78.0% | 69.4% |
| 营业利润率 | 1.8% | 27.2% |
| 净利率 | 23.1% | 15.8% |
| 营收同比 | 16.7% | 11.3% |
| 净利润同比 | 6.8% | 53.7% |
| 每股收益（稀释后） | $0.66 | $4.87 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EWROP
| Q1 26 | $1.6B | $2.1B | ||
| Q4 25 | $1.6B | $2.1B | ||
| Q3 25 | $1.6B | $2.0B | ||
| Q2 25 | $1.5B | $1.9B | ||
| Q1 25 | $1.4B | $1.9B | ||
| Q4 24 | $1.4B | $1.9B | ||
| Q3 24 | $1.4B | $1.8B | ||
| Q2 24 | $1.4B | $1.7B |
净利润EWROP
| Q1 26 | $380.7M | $331.0M | ||
| Q4 25 | $91.2M | $428.4M | ||
| Q3 25 | $291.1M | $398.5M | ||
| Q2 25 | $333.2M | $378.3M | ||
| Q1 25 | $358.0M | $331.1M | ||
| Q4 24 | $385.6M | $462.3M | ||
| Q3 24 | $3.1B | $367.9M | ||
| Q2 24 | $366.3M | $337.1M |
毛利率EWROP
| Q1 26 | 78.0% | 69.4% | ||
| Q4 25 | 78.1% | 69.5% | ||
| Q3 25 | 77.8% | 69.5% | ||
| Q2 25 | 77.5% | 69.2% | ||
| Q1 25 | 78.7% | 68.7% | ||
| Q4 24 | 78.9% | 68.3% | ||
| Q3 24 | 80.6% | 69.2% | ||
| Q2 24 | 79.9% | 69.5% |
营业利润率EWROP
| Q1 26 | 1.8% | 27.2% | ||
| Q4 25 | 9.6% | 28.6% | ||
| Q3 25 | 19.8% | 28.4% | ||
| Q2 25 | 26.8% | 28.2% | ||
| Q1 25 | 27.9% | 27.9% | ||
| Q4 24 | 22.6% | 28.0% | ||
| Q3 24 | 25.9% | 28.1% | ||
| Q2 24 | 26.8% | 28.8% |
净利率EWROP
| Q1 26 | 23.1% | 15.8% | ||
| Q4 25 | 5.8% | 20.8% | ||
| Q3 25 | 18.7% | 19.8% | ||
| Q2 25 | 21.7% | 19.5% | ||
| Q1 25 | 25.3% | 17.6% | ||
| Q4 24 | 27.8% | 24.6% | ||
| Q3 24 | 226.7% | 20.8% | ||
| Q2 24 | 26.7% | 19.6% |
每股收益（稀释后）EWROP
| Q1 26 | $0.66 | $4.87 | ||
| Q4 25 | $0.16 | $3.97 | ||
| Q3 25 | $0.50 | $3.68 | ||
| Q2 25 | $0.56 | $3.49 | ||
| Q1 25 | $0.61 | $3.06 | ||
| Q4 24 | $0.65 | $4.29 | ||
| Q3 24 | $5.13 | $3.40 | ||
| Q2 24 | $0.61 | $3.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $382.9M |
| 总债务越低越好 | — | $9.7B |
| 股东权益账面价值 | — | $18.8B |
| 总资产 | — | $34.6B |
| 负债/权益比越低杠杆越低 | — | 0.52× |
8季度趋势，按日历期对齐
现金及短期投资EWROP
| Q1 26 | — | $382.9M | ||
| Q4 25 | $4.2B | $297.4M | ||
| Q3 25 | $3.8B | $320.0M | ||
| Q2 25 | $4.1B | $242.4M | ||
| Q1 25 | $3.9B | $372.8M | ||
| Q4 24 | $4.0B | $188.2M | ||
| Q3 24 | $4.4B | $269.6M | ||
| Q2 24 | $2.0B | $251.5M |
总债务EWROP
| Q1 26 | — | $9.7B | ||
| Q4 25 | — | $9.3B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益EWROP
| Q1 26 | — | $18.8B | ||
| Q4 25 | $10.3B | $19.9B | ||
| Q3 25 | $10.2B | $20.0B | ||
| Q2 25 | $10.5B | $19.6B | ||
| Q1 25 | $10.1B | $19.2B | ||
| Q4 24 | $10.0B | $18.9B | ||
| Q3 24 | $9.5B | $18.5B | ||
| Q2 24 | $7.4B | $18.1B |
总资产EWROP
| Q1 26 | — | $34.6B | ||
| Q4 25 | $13.7B | $34.6B | ||
| Q3 25 | $13.3B | $34.6B | ||
| Q2 25 | $13.5B | $33.2B | ||
| Q1 25 | $13.0B | $31.4B | ||
| Q4 24 | $13.1B | $31.3B | ||
| Q3 24 | $13.0B | $31.6B | ||
| Q2 24 | $10.1B | $29.8B |
负债/权益比EWROP
| Q1 26 | — | 0.52× | ||
| Q4 25 | — | 0.47× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.40× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | — |
| 自由现金流经营现金流 - 资本支出 | — | $507.0M |
| 自由现金流率自由现金流/营收 | — | 24.2% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流EWROP
| Q1 26 | — | — | ||
| Q4 25 | $450.9M | $738.0M | ||
| Q3 25 | $573.7M | $869.5M | ||
| Q2 25 | $290.2M | $404.1M | ||
| Q1 25 | $280.4M | $528.7M | ||
| Q4 24 | $-127.5M | $722.2M | ||
| Q3 24 | $351.8M | $755.4M | ||
| Q2 24 | $371.5M | $384.1M |
自由现金流EWROP
| Q1 26 | — | $507.0M | ||
| Q4 25 | $353.5M | — | ||
| Q3 25 | $516.2M | — | ||
| Q2 25 | $240.9M | — | ||
| Q1 25 | $224.4M | — | ||
| Q4 24 | $-177.3M | — | ||
| Q3 24 | $299.9M | — | ||
| Q2 24 | $286.1M | — |
自由现金流率EWROP
| Q1 26 | — | 24.2% | ||
| Q4 25 | 22.5% | — | ||
| Q3 25 | 33.2% | — | ||
| Q2 25 | 15.7% | — | ||
| Q1 25 | 15.9% | — | ||
| Q4 24 | -12.8% | — | ||
| Q3 24 | 22.1% | — | ||
| Q2 24 | 20.9% | — |
资本支出强度EWROP
| Q1 26 | — | 0.5% | ||
| Q4 25 | 6.2% | — | ||
| Q3 25 | 3.7% | — | ||
| Q2 25 | 3.2% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 3.6% | — | ||
| Q3 24 | 3.8% | — | ||
| Q2 24 | 6.2% | — |
现金转化率EWROP
| Q1 26 | — | — | ||
| Q4 25 | 4.94× | 1.72× | ||
| Q3 25 | 1.97× | 2.18× | ||
| Q2 25 | 0.87× | 1.07× | ||
| Q1 25 | 0.78× | 1.60× | ||
| Q4 24 | -0.33× | 1.56× | ||
| Q3 24 | 0.11× | 2.05× | ||
| Q2 24 | 1.01× | 1.14× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
